- Two new bioconjugation suites to provide high throughput conjugation for the commercialization of antibody-drug conjugates (ADCs) in Lonza’s Ibex®Dedicate
- 1500m2 of active manufacturing space in addition to established quality control (QC) labs, logistics and other central services
- Long-term collaboration with a global biopharma company will generate around 200 new jobs in Visp (CH) biopark, with operations expected to start from end 2022
Quote from Pierre-Alain Ruffieux, CEO, Lonza:
"Bioconjugates represent an exciting class of molecules that are proving their worth and making a real difference to patients suffering from diseases such as cancer. From a manufacturing point of view, antibody-drug conjugates are challenging to produce, and we will be ensuring that our partner can de-risk supply and scale-up rapidly at this crucial moment of commercialization."
Quote from Jean-Christophe Hyvert, Chief Commercial Officer, Lonza:
"This collaboration demonstrates the power behind our Ibex® Dedicate model, providing rapid and reliable delivery of complex therapeutics and tailored to individual customer needs. Our Visp (CH) site now has all the elements required for antibody-drug conjugates at one site and this provides significant supply chain simplification and other logistical benefits to our customers, enabling them to reach patients faster."
Lonza today announced a long-term, strategic collaboration for bioconjugation with a global biopharma company. Under the terms of the agreement, Lonza will construct two new customer-dedicated conjugation suites for the commercialization of antibody-drug conjugates (ADCs) at its Visp (CH) site.
As part of Lonza’s Ibex® Dedicate model, a technology-agnostic supply solution that helps reduce time to market and control investment risk, two bioconjugation suites totaling 1500m2 of active manufacturing space will be built out within a pre-existing shell. The new suites will also benefit from established quality control (QC) labs, logistics and other central services, allowing for faster ramp-up times, assured delivery and high performance.
The high throughput bioconjugation suites will be capable of handling highly-potent materials for cancer therapies and will initially manufacture two therapies. The new dedicated facility will employ around 200 staff, with operations expected to start from the end of 2022.
ADC’s are bioconjugates and represent an innovative therapeutic modality that is growing rapidly and providing effective therapies to patients with reduced side effects. ADC’s usually combine an antibody with a highly-potent payload (via a linker molecule) to target cancer cells. The antibody serves as the delivery method to target the toxic drug precisely to cancer cells, limiting toxicity to healthy cells.
Lonza has developed the specific expertise and technology to de-risk the development and manufacturing of bioconjugates and now supports the majority of commercially approved ADCs. In addition, Lonza also offers all elements of a complex supply chain, including manufacturing of biomolecule, synthetic payload, linker and subsequent conjugation at a single site.
Additional Information and Disclaimer
Lonza Group Ltd has its headquarters in Basel, Switzerland, and is listed on the SIX Swiss Exchange. It has a secondary listing on the Singapore Exchange Securities Trading Limited ("SGX-ST"). Lonza Group Ltd is not subject to the SGX-ST’s continuing listing requirements but remains subject to Rules 217 and 751 of the SGX-ST Listing Manual.
Certain matters discussed in this news release may constitute forward-looking statements. These statements are based on current expectations and estimates of Lonza Group Ltd, although Lonza Group Ltd can give no assurance that these expectations and estimates will be achieved. Investors are cautioned that all forward-looking statements involve risks and uncertainty and are qualified in their entirety. The actual results may differ materially in the future from the forward-looking statements included in this news release due to various factors. Furthermore, except as otherwise required by law, Lonza Group Ltd disclaims any intention or obligation to update the statements contained in this news release.
At Lonza, we combine technological innovation with world class manufacturing and process excellence. Together, these enable our customers to deliver their discoveries in the healthcare, preservation, and protection sectors.
We are a preferred global partner to the pharmaceutical, biotech and specialty ingredients markets. We work to prevent illness and promote a healthier world by enabling our customers to deliver innovative medicines that help treat or even cure a wide range of diseases. We also offer a broad range of microbial control solutions, which help to create and maintain a healthy environment.
Founded in 1897 in the Swiss Alps, Lonza today operates in 120 sites and offices in more than 35 countries. With approximately 15,500 full-time employees, we are built from high-performing teams and of individual employees who make a meaningful difference to our own business, as well as the communities in which we operate. The company generated sales of CHF 5.9 billion in 2019 with a CORE EBITDA of CHF 1.6 billion. Find out more at www.lonza.com and follow us on Twitter @LonzaGroup or Facebook @LonzaGroupAG.
Lonza Group Ltd.
Münchensteinerstraße 38
CH4002 Basel
Telefon: +41 (61) 3168638
Telefax: +41 (61) 3169638
http://www.lonza.com
Head Public Relations
Telefon: +41 (61) 316-8929
E-Mail: sanna.fowler@lonza.com
Telefon: +41 (61) 316-8540
Fax: +41 (61) 316-9540
E-Mail: dirk.oehlers@lonza.com
